folic acid has been researched along with Malignant Mesothelioma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, M; Hirano, S; Katsuya, Y; Kobayashi, K; Naka, G; Suzuki, M; Takeda, Y; Uemura, Y | 1 |
| Bhosle, J; Gunapala, R; Hodgkiss, A; Kumar, R; Mak, D; Minchom, A; O'Brien, MER; Popat, S; Walder, D; Yousaf, N | 1 |
| Christoph, DC; Flom, E; Kollmeier, J; Mairinger, FD; Mairinger, T; Popper, HH; Schmid, KW; Vollbrecht, C; Walter, RFH | 1 |
| Mansfield, AS; Peikert, T; Symanowski, JT; Vogelzang, NJ | 1 |
1 trial(s) available for folic acid and Malignant Mesothelioma
| Article | Year |
|---|---|
Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Folic Acid; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Progression-Free Survival; Proportional Hazards Models; Tumor Burden; United States; Vitamin B 12; Vitamin B Complex | 2018 |
3 other study(ies) available for folic acid and Malignant Mesothelioma
| Article | Year |
|---|---|
Correlation of toxicities and efficacies of pemetrexed with clinical factors and single-nucleotide polymorphisms: a prospective observational study.
Topics: Carcinoma, Non-Small-Cell Lung; Folic Acid; Humans; Lung Neoplasms; Mesothelioma, Malignant; Pemetrexed; Polymorphism, Single Nucleotide | 2023 |
A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Carcinoma, Non-Small-Cell Lung; Depression; Dietary Supplements; Female; Folic Acid; Homocysteine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Prospective Studies; Treatment Outcome; Vitamin B 12; Vitamins | 2019 |
Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Folic Acid; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Peptide Synthases; Phenotype; Pleural Neoplasms; Prognosis; Reduced Folate Carrier Protein; Thymidylate Synthase; Treatment Outcome | 2017 |